REVIEW ARTICLE E. David Crawford, Thomas W. Flaig;ONCOLOGY Vol. 26 No. 1
We have entered a period of accelerated drug development and optimism in the care of advanced prostate cancer. Future study is needed to define the optimal sequencing and potential combinations of these new agents.
REVIEW ARTICLE Kyle O. Rove, E. David Crawford;ONCOLOGY Vol. 25 No. 14
This review will examine agents with potential activity in the palliation and treatment of skeletal metastases of PCa, and will weigh the clinical-outcomes evidence for and against their broad use.
REVIEW ARTICLE Rian J. Dickstein, Ashish M. Kamat, MD; ONCOLOGY Vol. 25 No. 14
Muscle-invasive bladder cancer is an aggressive and potentially lethal disease. Integration of multimodal therapies, improved surgical techniques, and utilization of targeted agents has tremendously improved outcomes.
CLINICAL QUANDARIES Waseem Khaliq, Ikechukwu Uzoaru, et al; ONCOLOGY Vol. 24 No. 9
Here we present the first case of a radiation-resistant solitary plasmacytoma of the bladder that was successfully treated with lenalidomide and dexamethasone with successful clinical remission.
SECOND OPINION Elaine T. Lam et al;ONCOLOGY Vol. 25 No. 9
The patient is a 43-year-old man who was initially evaluated at an outside institution for unexplained anemia and who was found to have a large right kidney mass. He underwent a radical nephrectomy for a 19-cm large-cell, poorly differentiated neoplasm.
SECOND OPINION Thomas W. Flaig, Francisco G. La Rosa, et al;ONCOLOGY Vol. 23 No. 2
The patient is a 39-year-old man who presents with pelvic lymphadenopathy. He has a history of ureteral reflux disease, recurrent nephrolithiasis, right nephrectomy, ileal loop diversion of the left ureter, and radical cystectomy for “bladder cancer,” which he underwent 3 years ago. The lymphadenopathy was discovered incidentally during recent imaging.
REVIEW ARTICLES
The State of Prostate MRI in 2013 Rajan T. Gupta, MD1,
Christopher R. Kauffman, MD1,
Thomas J. Polascik, MD, FACS2,
Samir S. Taneja, MD3,
Andrew B. Rosenkrantz, MD4, April 15, 2013
Our aims in this article are to describe the various imaging sequences that comprise the multiparametric MRI exam, as well as to review current literature on the strengths/weaknesses of these sequences; to delineate strategies for standardizing interpretation and reporting of MRI results; and to expound on the role of prostate MRI in clinical practice.
• The State of Prostate MRI in 2013: Into the Breach • Multiparametric MRI: Standardizations Needed
This review summarizes recent findings in clinical prostate cancer research reported at the 2012 Annual Scientific Meeting of the American Society of Clinical Oncology (ASCO) and addresses their relevance to clinical practice.
• Prostate Cancer 2012: Where Do We Stand and Where Are We Heading?
We describe areas where major inroads were initially achieved by targeting angiogenesis and by unraveling
pathways in the heterogeneous tumors of mesenchymal origin—spurred by the identification of c-Kit–activating
mutations in GIST and the regressions that ensued when tumors harboring these mutations were exposed to the
tyrosine kinase inhibitor imatinib (Gleevec).
• Improving Harmonious Precision • Targeted Therapy for Cancer: Asking the Right Questions
A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?
A 28-year-old man presents with testicular pain of several weeks duration. Physical examination discloses the presence of a right testicular mass. Orchiectomy is performed. What is your Diagnosis?
A 63-year-old man presents with symptoms of blood in the urine that has lasted for several days. Cystoscopic examination reveals the presence of a small tumor mass in the trigone of the bladder. Surgical resection is performed.
A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction... More »
Two genome-wide studies have identified a total of 12 new genetic loci associated with a higher risk of testicular cancer. The risk-associated genetic... More »
The American Urological Association (AUA) released a new clinical guideline detailing recommendations for the use of prostate cancer screening in... More »
Radium-223 dichloride (Xofigo) received FDA approval for the treatment of symptomatic metastatic castration-resistant prostate cancer that has... More »
The majority of patients with systemic prostate cancer treated with androgen deprivation therapy (ADT) will develop castration-resistant prostate... More »
Ahead of the ASCO GU meeting, we spoke with two symposium committee members, Dr. Mack Roach, of the University of California, San Francisco, and Dr. Hans T. Chung, of the University of Toronto, about early treatment and surveillance of prostate cancer patients.
Our aims in this article are to describe the various imaging sequences that comprise the multiparametric MRI exam, as well as to review current literature on the strengths/weaknesses of these sequences; to delineate strategies for standardizing interpretation and reporting of MRI results; and to expound on the role of prostate MRI in clinical practice.
In this review we focus on the recent evolution of the concept of focal therapy and the potential applications of this management approach within an array of options currently available for patients with localized prostate cancer.
This review summarizes recent findings in clinical prostate cancer research reported at the 2012 Annual Scientific Meeting of the American Society of Clinical Oncology (ASCO) and addresses their relevance to clinical practice.
We describe areas where major inroads were initially achieved by targeting angiogenesis and by unraveling
pathways in the heterogeneous tumors of mesenchymal origin—spurred by the identification of c-Kit–activating
mutations in GIST and the regressions that ensued when tumors harboring these mutations were exposed to the
tyrosine kinase inhibitor imatinib (Gleevec).
A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?
A 28-year-old man presents with testicular pain of several weeks duration. Physical examination discloses the presence of a right testicular mass. Orchiectomy is performed. What is your Diagnosis?
A 63-year-old man presents with symptoms of blood in the urine that has lasted for several days. Cystoscopic examination reveals the presence of a small tumor mass in the trigone of the bladder. Surgical resection is performed.
An asymptomatic, 57-year-old man underwent a prostatic biopsy.
Ahead of the ASCO GU meeting, we spoke with two symposium committee members, Dr. Mack Roach, of the University of California, San Francisco, and Dr. Hans T. Chung, of the University of Toronto, about early treatment and surveillance of prostate cancer patients.
